A Trial of SHR-1210 in Combination With Apatinib in Patients With Unresectable HCC
Status:
Unknown status
Trial end date:
2021-01-30
Target enrollment:
Participant gender:
Summary
This is a Phase II , Open-label , Investigator-initiated Trail of SHR-1210 (an Anti-PD-1
Inhibitor) in Combination With Apatinib in Patients With unresectable Hepatocellular
Carcinoma.
This study aims to evaluate the safety and efficacy of SHR-1210 combination with Apatinib as
a preoperative treatment of unresectable HCC.